Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification.
Xiaoxiao HuYilu ZhouCharlotte HillKai ChenCheng ChengXiaowei LiuPeiwen DuanYaoyao GuYeming WuRob M EwingZhongrong LiZhixiang WuYihua WangPublished in: British journal of cancer (2024)
We propose that transcriptional subtyping may enhance precision prognosis and therapy stratification for patients with MYCN non-amplified neuroblastomas.